Skip Navigation
Skip to contents

ACC : Acute and Critical Care

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > Acute Crit Care > Volume 39(4); 2024 > Article
Corrigendum Corrigendum to: Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study
Acute and Critical Care 2024;39(4):652-653.
DOI: https://doi.org/10.4266/acc.2023.00983.e1
Published online: November 28, 2024

1Department of Anaesthesiology, All India Institute of Medical Sciences (AIIMS) Patna, Patna, India

2Department of Anaesthesiology, All India Institute of Medical Sciences (AIIMS) Bhubaneswar, Bhubaneswar, India

3Department of Anaesthesiology, Acharya Harihar Post Graduate Institute of Cancer, Cuttack, India

Corresponding Author: Neeraj Kumar Department of Anaesthesiology, All India Institute of Medical Sciences (AIIMS) Patna, Room no. 505, IPD 5th floor, OT complex, Patna, Bihar 801505 India Tel: +91-8210104972, Email: neeraj.jlnmc@gmail.com
• Received: November 22, 2024   • Accepted: November 22, 2024

© 2024 The Korean Society of Critical Care Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 604 Views
  • 29 Download
prev
Full Article

Download PDF Download PDF

This corrects the article "Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study" on page 234.
Acute and Critical Care 2024;39:234-242
https://doi.org/10.4266/acc.2023.00983
In the article entitled “Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study”, following corrections should be noted as pointed out by a readers.
1. Introduction
“Some studies have shown promising results with itolizumab, but no randomized controlled trial has confirmed its effectiveness. Although itolizumab has a similar mechanism of action to tocilizumab, no available study compares the two drugs in the management of COVID-19.” should be replaced by “Some studies have shown promising results with itolizumab, but there are limited randomized controlled trials comparing itolizumab with tocilizumab or control in the management of COVID-19 [1,2].”
2. Discussion
“First, it is the first study to compare itolizumab with tocilizumab in the treatment of COVID-19.” should be replaced by “First, we conducted this study on a large population as compared to previous studies [1,2].”
3. Table 2
The footnotes a) and b) in serious adverse event in should be corrected as
a) High-grade fever: 2, arrhythmia: 1; b) High-grade fever: 2, bronchospasm: 2, liver dysfunction: 1.
  • 1. Kumari P, Sinha C, Kumar A, Kumar A, Shettru KA, Kandrakonda PK. Comparative study of tocilizumab versus itolizumab in coronavirus disease 2019-infected patients: a randomized controlled trial. Res Opin Anesth Intensive Care 2023;10:1-6.
  • 2. Kumar S, De Souza R, Nadkar M, Guleria R, Trikha A, Joshi SR, et al. A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19. Expert Opin Biol Ther 2021;21:675-86.ArticlePubMedPMC

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      • PubReader PubReader
      • ePub LinkePub Link
      • Cite
        CITE
        export Copy
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Corrigendum to: Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study
        Acute Crit Care. 2024;39(4):652-653.   Published online November 28, 2024
        DOI: https://doi.org/10.4266/acc.2023.00983.e1
        Close
      • XML DownloadXML Download
      Related articles
      Corrigendum to: Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study
      Corrigendum to: Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study
      ACC : Acute and Critical Care
      © The Korean Society of Critical Care Medicine.
      TOP